Premitha Damodaran
Research Subjects
Research Interests
Premitha Damodaran has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Swan Sim Yeap
Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
2 shared publications Ai Lee Lim
Hospital Pulau Pinang, Pulau Pinang, Malaysia
1 shared publication- Alan Swee Hock Ch’ng
Clinical Research Centre (CRC) Hospital Seberang Jaya, Institute for Clinical Research, Ministry of Health Malaysia (MOH)
1 shared publication Alexander Tong Boon Tan
Sunway Medical Centre, Petaling Jaya, Selangor, Malaysia
1 shared publicationBoon Ping Lim
Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
1 shared publication- Chrisandra Shufelt
Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Functional hypothalamic amenorrhea: A call for global awareness and research
Functional hypothalamic amenorrhea (FHA) is a common yet under-recognized cause of secondary amenorrhea resulting from reversible suppression of the hypothalamic–pituitary–ovarian axis. Triggered by chronic stress, low energy availability, disordered eating, and/or excessive exercise, FHA leads not only to anovulation and hypoestrogenism but also to broader neuroendocrine disruption involving the hypothalamic–pituitary–adrenal and thyroid axes. Although historically associated with extreme trauma and the “female athlete triad,” FHA occurs worldwide and remains significantly underdiagnosed across diverse cultural and socioeconomic settings. Beyond reproductive consequences, FHA has been associated with reduced bone density, endothelial dysfunction, adverse cardiometabolic profiles, sexual dysfunction, mood disorders, and cognitive symptoms, while potential effects on brain and gut physiology remain less established. Despite these multisystem concerns, evidence-based treatment strategies are limited, and diagnosis is often delayed due to stigma, normalization of menstrual irregularities, and lack of clinical awareness. There is a critical need for global education, standardized diagnostic and management guidelines, mechanistic research to define long-term risks, and development of targeted interventions that restore both ovarian function and underlying neuroendocrine health. In this clinical perspective, we highlight key gaps and priorities to improve recognition, management, and long-term outcomes. FHA should be recognized as an important marker of overall well-being and a call to advance scientific understanding and care for affected individuals worldwide.
- 16 October 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Open AccessFunctional hypothalamic amenorrhea: A call for global awareness and research
Functional hypothalamic amenorrhea (FHA) is a common yet under-recognized cause of secondary amenorrhea resulting from reversible suppression of the hypothalamic–pituitary–ovarian axis. Triggered by chronic stress, low energy availability, disordered eating, and/or excessive exercise, FHA leads not only to anovulation and hypoestrogenism but also to broader neuroendocrine disruption involving the hypothalamic–pituitary–adrenal and thyroid axes. Although historically associated with extreme trauma and the “female athlete triad,” FHA occurs worldwide and remains significantly underdiagnosed across diverse cultural and socioeconomic settings. Beyond reproductive consequences, FHA has been associated with reduced bone density, endothelial dysfunction, adverse cardiometabolic profiles, sexual dysfunction, mood disorders, and cognitive symptoms, while potential effects on brain and gut physiology remain less established. Despite these multisystem concerns, evidence-based treatment strategies are limited, and diagnosis is often delayed due to stigma, normalization of menstrual irregularities, and lack of clinical awareness. There is a critical need for global education, standardized diagnostic and management guidelines, mechanistic research to define long-term risks, and development of targeted interventions that restore both ovarian function and underlying neuroendocrine health. In this clinical perspective, we highlight key gaps and priorities to improve recognition, management, and long-term outcomes. FHA should be recognized as an important marker of overall well-being and a call to advance scientific understanding and care for affected individuals worldwide.
- Open Access
- 20 June 2023
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 9 (2) , 60-69
A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
- 20 June 2023
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 9 (2) , 60-69
Open AccessA summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
- 24 January 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 16 (1) , 30-40
The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Aim: This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with osteoporosis (OP), using the best available evidence.Methods: A literature search using PubMed (MEDLINE) and The Cochrane Library identified all relevant articles on OP and its assessment, diagnosis and treatment, from 2005, to update from the previous edition published in 2006. The studies were assessed and the level of evidence assigned; for each statement, studies with the highest level of evidence were used to frame the recommendation.Results: This article summarizes the diagnostic and treatment pathways for OP, highlighting the new data that have changed the way we assess and treat OP. Instead of starting treatment based on bone mineral density alone, there has been a move to assessing 10‐year fracture risk before treatment, using tools such as the Fracture Risk Assessment Tool (FRAX). There has been a re‐evaluation on calcium supplementation and more emphasis on the importance of vitamin D. There has been concern about the potential adverse effects of the long‐term usage of bisphosphonates, which we have discussed fully. New drugs that have been licensed since 2006 in Malaysia have been included.Conclusions: Adequate intake of calcium (1000 mg from both diet and supplements) and vitamin D (800 IU) daily remain important in the treatment of OP. However, in confirmed OP, pharmacological therapy with anti‐resorptives is the mainstay of treatment. Patients need to be regularly assessed while on medication and treatment adjusted as required.
- 24 January 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 16 (1) , 30-40
The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Aim: This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with osteoporosis (OP), using the best available evidence.Methods: A literature search using PubMed (MEDLINE) and The Cochrane Library identified all relevant articles on OP and its assessment, diagnosis and treatment, from 2005, to update from the previous edition published in 2006. The studies were assessed and the level of evidence assigned; for each statement, studies with the highest level of evidence were used to frame the recommendation.Results: This article summarizes the diagnostic and treatment pathways for OP, highlighting the new data that have changed the way we assess and treat OP. Instead of starting treatment based on bone mineral density alone, there has been a move to assessing 10‐year fracture risk before treatment, using tools such as the Fracture Risk Assessment Tool (FRAX). There has been a re‐evaluation on calcium supplementation and more emphasis on the importance of vitamin D. There has been concern about the potential adverse effects of the long‐term usage of bisphosphonates, which we have discussed fully. New drugs that have been licensed since 2006 in Malaysia have been included.Conclusions: Adequate intake of calcium (1000 mg from both diet and supplements) and vitamin D (800 IU) daily remain important in the treatment of OP. However, in confirmed OP, pharmacological therapy with anti‐resorptives is the mainstay of treatment. Patients need to be regularly assessed while on medication and treatment adjusted as required.